Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma 2Rectal Neoplasms 1Oligodendroglioma 1Meningioma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Gliosarcoma 1Glioma 1Glioblastoma 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Oxaliplatin 16Irinotecan 12Fluorouracil 12Leucovorin 10Bevacizumab 8pembrolizumab 7Cetuximab 7Capecitabine 7Nivolumab 5Gemcitabine 5Cyclophosphamide 5fludarabine 4aldesleukin 4Panitumumab 4Folfox protocol 4oblimersen 3Interleukin-2 3selpercatinib 2poly ICLC 2labetuzumab 2dehydroftorafur 2conatumumab 2cemiplimab 2bintrafusp alfa protein, human 2Tomography, X-Ray Computed 2Specimen Handling 2Receptor Protein-Tyrosine Kinases 2Radiotherapy 2Levoleucovorin 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Colonic Neoplasms × Semaxinib × Clear all
NCT00005818 2013-01-23

SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
68 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡